Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

(2020) Qiurong Ruan et al.   INTENSIVE CARE MEDICINE

Autophagy and Protein Secretion

(2020) Giulio Cavalli et al.   JOURNAL OF MOLECULAR BIOLOGY

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

(2020) Achille Aouba et al.   ANNALS OF THE RHEUMATIC DISEASES

IL‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement

(2020) James W. Day et al.   BRITISH JOURNAL OF HAEMATOLOGY

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

(2020) George Dimopoulos et al.   Cell Host & Microbe

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

(2020) Corrado Campochiaro et al.   European Journal of Internal Medicine

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report

(2020) Marco Franzetti et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

(2020) Emanuele Pontali et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

(2020) Emanuel Della-Torre et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

(2020) Carlos Sanchez-Piedra et al.   ANNALS OF THE RHEUMATIC DISEASES

Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19

(2020) Raphaël Cauchois et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment

(2020) Andrés González-García et al.   RHEUMATOLOGY

Decreased in-hospital mortality in patients with COVID-19 pneumonia

(2020) Fabio Ciceri et al.   Pathogens and Global Health

Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series

(2020) Iris Navarro‐Millán et al.   Arthritis & Rheumatology

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

(2020) Christoph D. Spinner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drug retention rates of biological agents in adult onset Still's disease

(2020) Corrado Campochiaro et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

(2019) Esraa M. Eloseily et al.   Arthritis & Rheumatology

Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature

(2018) Hafize Emine Sönmez et al.   CLINICAL RHEUMATOLOGY

Myocarditis: An Interleukin-1-Mediated Disease?

(2018) Giacomo De Luca et al.   Frontiers in Immunology

Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition

(2018) Giacomo De Luca et al.   ANNALS OF INTERNAL MEDICINE

Anakinra Therapy for Non-cancer Inflammatory Diseases

(2018) Giulio Cavalli et al.   Frontiers in Pharmacology

Acute Respiratory Distress Syndrome

(2017) B. Taylor Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure

(2017) Giulio Cavalli et al.   Frontiers in Immunology

Treating Life-Threatening Myocarditis by Blocking Interleukin-1*

(2016) Giulio Cavalli et al.   CRITICAL CARE MEDICINE

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome

(2016) Bita Shakoory et al.   CRITICAL CARE MEDICINE

Macrophage activation syndrome in the era of biologic therapy

(2016) Alexei A. Grom et al.   Nature Reviews Rheumatology

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat

(2016) Angelo Ravelli et al.   Arthritis & Rheumatology

Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)

(2015) Antonio Abbate et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and safety of biological agents in adult-onset Still’s disease

(2015) G Cavalli et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients

(2014) Francesca Minoia et al.   Arthritis & Rheumatology

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

(2011) C. A. Dinarello   BLOOD

Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases

(2008) S. Fukaya et al.   RHEUMATOLOGY